Related Experiment Videos
The WHO-IUIS International Reference Preparations for Allergens: drawbacks
1Research Group C.B.F. Leti, S.A., Tres Cantos, Madrid, Spain.
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Novel approaches to immunotherapy: epitopes, determinants, activators, or modulators?
Allergologia et immunopathologia·1998
Complement activating agents in allergenic extracts.
Inflammation research : official journal of the European Histamine Research Society ... [et al.]·1998
The role of IgG in type-I allergy: an unsolved problem.
Journal of investigational allergology & clinical immunology·1997
Comparative study of the complement-activating and specific IgE-binding properties of ragweed pollen allergen.
Clinical and experimental immunology·1997
Haemolytic complement consumption by Parietaria pollen extracts in relation to peptide-bound flavonoids.
Cellular and molecular life sciences : CMLS·1997
Complement inactivation by allergenic plant pollen extracts.
Life sciences·1997
A bright future for sublingual immunotherapy--contra.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Recent advances in the use of genetically engineered negative signaling molecules to treat allergic diseases.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Prospects for CpG based immunotherapy in asthma and allergy.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Understanding the immunological basis of asthma; immunotherapy and regulatory T cells.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Recombinant and modified allergens: the U.S. perspective.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Clinical trials with allergen products: in search of biological markers of efficacy.
Arbeiten aus dem Paul-Ehrlich-Institut (Bundesamt fur Sera und Impfstoffe) zu Frankfurt a.M·2007
Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.
Frontiers in immunology·2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Frontiers in immunology·2026